Rentokil Initial plc Sponsored ADR logo

Rentokil Initial plc Sponsored ADR (RTO)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
21. 09
+0.27
+1.2968%
$
10.19B Market Cap
28.14 P/E Ratio
0.11% Div Yield
2.1M Volume
0 Eps
$ 20.82
Previous Close
Add Transaction
Day Range
20.96 21.18
Year Range
19.5 34.67
Want to track RTO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
European stocks set for another mixed open as Iran peace efforts remain unclear

European stocks set for another mixed open as Iran peace efforts remain unclear

European stocks are expected to open in mixed territory as investors assess a confused picture of where the Iran war and peace talks are headed.

Cnbc | 6 months ago
Rentokil Initial (NYSE:RTO) versus VCI Global (NASDAQ:VCIG) Financial Analysis

Rentokil Initial (NYSE:RTO) versus VCI Global (NASDAQ:VCIG) Financial Analysis

VCI Global (NASDAQ: VCIG - Get Free Report) and Rentokil Initial (NYSE: RTO - Get Free Report) are both business services companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Analyst Ratings This is a summary of

Defenseworld | 7 months ago
Rentokil 2025 Earnings: Looking Beyond The Market's Advance Praise

Rentokil 2025 Earnings: Looking Beyond The Market's Advance Praise

Rentokil Initial plc (RTO) shows stabilization in 2025, with North America organic growth improving and streamlining efforts beginning to yield results. RTO's recurring significant earnings adjustments and complex reporting continue to obscure true underlying performance, justifying a valuation discount. Leverage remains elevated at 7.5x free cash flow, and although free cash flow covers the dividend, the balance sheet is not robust.

Seekingalpha | 7 months ago
Rentokil: A Bug Business With Long-Term Bite

Rentokil: A Bug Business With Long-Term Bite

Rentokil (RTO) offers a more attractive valuation and diversified growth profile than peer Rollins, trading at a significant discount despite similar growth drivers. RTO reported FY'25 revenues of $6.91B (+3.8% YoY), with organic growth, margin expansion, and strong free cash flow supporting deleveraging and investment-grade credit ratings. Industry tailwinds, operational efficiencies, and a robust M&A pipeline underpin expectations for mid-to-high single-digit EPS growth and margin improvement toward 20%+ by 2027.

Seekingalpha | 7 months ago
Rentokil Initial plc (RTO) Q4 2025 Earnings Call Transcript

Rentokil Initial plc (RTO) Q4 2025 Earnings Call Transcript

Rentokil Initial plc (RTO) Q4 2025 Earnings Call Transcript

Seekingalpha | 7 months ago
Rentokil jumps as US pest control momentum improves

Rentokil jumps as US pest control momentum improves

Shares in Rentokil Initial PLC jumped 9.2% to 464.6p on Thursday as the pest control giant reported full-year results that met or beat market expectations, helped by improving momentum in North America. Revenue from continuing operations rose 4.4% to $6.9 billion and adjusted operating profit climbed 5.4% to $1.1 billion, both in line with the $6.9 billion City analyst consensus.

Proactiveinvestors | 7 months ago
Rentokil Initial Reports Higher Revenue Amid Leadership Transition

Rentokil Initial Reports Higher Revenue Amid Leadership Transition

The pest-control, hygiene and workwear-services provider's revenue climbed 2.6% organically in 2025.

Wsj | 7 months ago
Roquefort Therapeutics to acquire cancer drug licence in £32m RTO deal and raise £8.5m

Roquefort Therapeutics to acquire cancer drug licence in £32m RTO deal and raise £8.5m

Roquefort Therapeutics PLC (LSE:ROQ),a biotech company currently valued at less than £1.5 million, is set to be transformed into a clinical-stage oncology business after announcing the £32 million acquisition of an exclusive worldwide licence to a promising cancer drug alongside a £8.5 million fundraise. The company is acquiring the rights to AO-252, an orally administered small molecule drug targeting TACC3, a protein that is over-expressed in many aggressive tumours, from Coiled Therapeutics, a spin-out of A2A Pharma Pharmaceuticals.

Proactiveinvestors | 7 months ago
Rentokil downgraded as analysts warn pest control margins lag far behind global peers

Rentokil downgraded as analysts warn pest control margins lag far behind global peers

Rentokil Initial PLC (LSE:RTO) has been downgraded from 'buy' to 'hold' at Deutsche Bank, with the target price cut from 505p to 465p. Analysts frame the thesis carefully.

Proactiveinvestors | 7 months ago
What Makes Rentokil Initial (RTO) a New Buy Stock

What Makes Rentokil Initial (RTO) a New Buy Stock

Rentokil Initial (RTO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 10 months ago
Has Rentokil Initial (RTO) Outpaced Other Business Services Stocks This Year?

Has Rentokil Initial (RTO) Outpaced Other Business Services Stocks This Year?

Here is how Rentokil Initial PLC (RTO) and SGS SA (SGSOY) have performed compared to their sector so far this year.

Zacks | 10 months ago
RTO or TRI: Which Is the Better Value Stock Right Now?

RTO or TRI: Which Is the Better Value Stock Right Now?

Investors interested in Business - Services stocks are likely familiar with Rentokil Initial PLC (RTO) and Thomson Reuters (TRI). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks | 11 months ago
Loading...
Load More